Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Changes in left ventricular function during chemotherapy with doxorubicin].

L Elbl1, V Chaloupka, I Vásová

  • 1Oddĕlení funkcního vysetrování FN, Brno.

Vnitrni Lekarstvi
|October 25, 2000
PubMed
Summary

Doxorubicin chemotherapy can cause gradual decline in left ventricular ejection fraction in lymphoma patients, impacting diastolic function early. These cardiac changes, though not requiring intervention, warrant long-term follow-up for potential late sequelae.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of online-delivered controlled physical activity on cardiorespiratory fitness and heart rate variability in breast cancer survivors.

Scientific reports·2026
Same author

Prevalence of Chlamydia trachomatis and Neisseria gonorrhoeae in women of the Czech Republic armed forces.

Epidemiologie, mikrobiologie, imunologie : casopis Spolecnosti pro epidemiologii a mikrobiologii Ceske lekarske spolecnosti J.E. Purkyne·2025
Same author

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial.

ESMO open·2025
Same author

Predictors of maintaining motivation to exercise in women with breast cancer - preliminary results of a qualitative study.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025
Same author

Neoadjuvant treatment of locally advanced rectal cancer - a consensus procedure Comprehensive Cancer Center Brno.

Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti·2025
Same author

Current real-world evidence on characteristics and treatment patterns of lung cancer in the single cancer center in the Czech Republic -  data from Masaryk Memorial Cancer Institute registry in 2018- 2022.

Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti·2025

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Context:

  • Doxorubicin is a common chemotherapy agent used for lymphoma.
  • Cardiotoxicity is a known side effect of anthracycline chemotherapy.
  • Left ventricular dysfunction can occur during doxorubicin treatment.

Purpose:

  • To investigate echocardiographic changes in left ventricular function in patients receiving doxorubicin chemotherapy.
  • To assess the correlation between doxorubicin dosage and cardiac function.
  • To evaluate the predictive value of diastolic dysfunction for systolic dysfunction.

Summary:

  • Echocardiography revealed a significant decline in left ventricular ejection fraction in 22% of patients treated with doxorubicin for lymphoma.
  • Early diastolic dysfunction, indicated by prolonged isovolumic relaxation period and deceleration time, was observed after a cumulative dose of 100 mg/m2.

Related Experiment Videos

  • These functional changes correlated with increased end-systolic stress but did not necessitate chemotherapy alteration or indicate immediate cardiac failure.
  • Patient age was the only clinical factor significantly related to diastolic dysfunction indicators.

    • Impact:

    • The study highlights the importance of monitoring cardiac function during doxorubicin therapy.
    • Early detection of diastolic dysfunction may not predict immediate systolic dysfunction but warrants long-term surveillance.
    • Findings suggest that current functional changes may not warrant chemotherapy interruption but emphasize the need for long-term follow-up for late anthracycline-induced cardiotoxicity.